WO2009043136A1 - Improving the energy status of an individual by enhanced usage of an endogenous fuel source - Google Patents
Improving the energy status of an individual by enhanced usage of an endogenous fuel source Download PDFInfo
- Publication number
- WO2009043136A1 WO2009043136A1 PCT/CA2007/001782 CA2007001782W WO2009043136A1 WO 2009043136 A1 WO2009043136 A1 WO 2009043136A1 CA 2007001782 W CA2007001782 W CA 2007001782W WO 2009043136 A1 WO2009043136 A1 WO 2009043136A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactate
- derivative
- pyruvate
- glutamine
- leucine
- Prior art date
Links
- 239000000446 fuel Substances 0.000 title description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims abstract description 128
- 239000002243 precursor Substances 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 27
- 230000002473 insulinotropic effect Effects 0.000 claims abstract description 25
- 239000000048 adrenergic agonist Substances 0.000 claims abstract description 21
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims abstract description 11
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical group CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 25
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 20
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 13
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 13
- 150000004728 pyruvic acid derivatives Chemical class 0.000 claims description 13
- 239000004475 Arginine Substances 0.000 claims description 11
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 11
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 11
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 11
- 229960001948 caffeine Drugs 0.000 claims description 11
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 10
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 7
- CWKLZLBVOJRSOM-UHFFFAOYSA-N methyl pyruvate Chemical compound COC(=O)C(C)=O CWKLZLBVOJRSOM-UHFFFAOYSA-N 0.000 claims description 5
- WXUAQHNMJWJLTG-VKHMYHEASA-N (S)-methylsuccinic acid Chemical compound OC(=O)[C@@H](C)CC(O)=O WXUAQHNMJWJLTG-VKHMYHEASA-N 0.000 claims description 3
- 150000003893 lactate salts Chemical class 0.000 claims description 3
- 150000001483 arginine derivatives Chemical class 0.000 claims 10
- 150000002309 glutamines Chemical class 0.000 claims 10
- 150000002614 leucines Chemical class 0.000 claims 10
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 4
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 4
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- 230000002708 enhancing effect Effects 0.000 abstract description 6
- 230000001965 increasing effect Effects 0.000 description 40
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 28
- 230000000694 effects Effects 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 20
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 18
- 210000003205 muscle Anatomy 0.000 description 17
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 16
- 229930182837 (R)-adrenaline Natural products 0.000 description 14
- 102000004877 Insulin Human genes 0.000 description 14
- 108090001061 Insulin Proteins 0.000 description 14
- 229960005139 epinephrine Drugs 0.000 description 14
- 229940125396 insulin Drugs 0.000 description 14
- 239000002775 capsule Substances 0.000 description 13
- 238000004090 dissolution Methods 0.000 description 12
- 235000015872 dietary supplement Nutrition 0.000 description 11
- 230000004060 metabolic process Effects 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 239000004310 lactic acid Substances 0.000 description 10
- 235000014655 lactic acid Nutrition 0.000 description 10
- 229940076788 pyruvate Drugs 0.000 description 10
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 9
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 9
- 108060003345 Adrenergic Receptor Proteins 0.000 description 9
- 102000017910 Adrenergic receptor Human genes 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 241000282412 Homo Species 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 230000037081 physical activity Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000003801 milling Methods 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 208000010444 Acidosis Diseases 0.000 description 6
- 206010027417 Metabolic acidosis Diseases 0.000 description 6
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 6
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 6
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000003914 insulin secretion Effects 0.000 description 6
- 210000002027 skeletal muscle Anatomy 0.000 description 6
- 230000000153 supplemental effect Effects 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 229920002527 Glycogen Polymers 0.000 description 4
- 102000017298 Monocarboxylate transporters Human genes 0.000 description 4
- 108050005244 Monocarboxylate transporters Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 150000003943 catecholamines Chemical class 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 229940096919 glycogen Drugs 0.000 description 4
- 230000034659 glycolysis Effects 0.000 description 4
- 229960003136 leucine Drugs 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102100025276 Monocarboxylate transporter 4 Human genes 0.000 description 3
- 239000000808 adrenergic beta-agonist Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000006538 anaerobic glycolysis Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000007882 dietary composition Nutrition 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000014268 sports nutrition Nutrition 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 description 2
- 101000577126 Homo sapiens Monocarboxylate transporter 4 Proteins 0.000 description 2
- 101000577129 Homo sapiens Monocarboxylate transporter 5 Proteins 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 229950006790 adenosine phosphate Drugs 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 2
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 2
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 2
- 230000037147 athletic performance Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940117360 ethyl pyruvate Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 150000002308 glutamine derivatives Chemical class 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 150000002871 norepinephrines Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229950007002 phosphocreatine Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 210000002363 skeletal muscle cell Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- OZZQHCBFUVFZGT-UHFFFAOYSA-N 2-(2-hydroxypropanoyloxy)propanoic acid Chemical compound CC(O)C(=O)OC(C)C(O)=O OZZQHCBFUVFZGT-UHFFFAOYSA-N 0.000 description 1
- MGRMBPNPJVCMIP-UHFFFAOYSA-N 2-oxopropanoic acid hydrate Chemical compound O.C(C(=O)C)(=O)O.C(C(=O)C)(=O)O MGRMBPNPJVCMIP-UHFFFAOYSA-N 0.000 description 1
- 108010046716 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) Proteins 0.000 description 1
- JDRMYOQETPMYQX-UHFFFAOYSA-M 4-methoxy-4-oxobutanoate Chemical compound COC(=O)CCC([O-])=O JDRMYOQETPMYQX-UHFFFAOYSA-M 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108091006601 SLC16A3 Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- -1 arginine Chemical class 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- JDRMYOQETPMYQX-UHFFFAOYSA-N butanedioic acid monomethyl ester Natural products COC(=O)CCC(O)=O JDRMYOQETPMYQX-UHFFFAOYSA-N 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008519 endogenous mechanism Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000023266 generation of precursor metabolites and energy Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000037447 lactate metabolism Effects 0.000 description 1
- 150000003903 lactic acid esters Chemical class 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 230000012042 muscle hypertrophy Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000001797 obstructive sleep apnea Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008160 regulation of oxidative phosphorylation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000476 thermogenic effect Effects 0.000 description 1
- 239000010891 toxic waste Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Definitions
- the present invention relates to methods and compositions for improving the energy status of an individual by enhancing the usage of an endogenously produced energy source.
- ATP adenosine triphosphate
- Aerobic metabolism involves a complicated series of reactions to produce energy. In terms of efficiency, aerobic metabolism provides more energy than anaerobic metabolism. Aerobic respiration is used to provide energy during endurance-type activities which are typified by low- to moderate-intensity activities maintained for long durations (Korzeniewski B. Regulation of oxidative phosphorylation in different muscles and various experimental conditions. Biochem J. 2003 Nov l;375(Pt 3):799-804).
- Anaerobic glycolysis is utilized for energy when aerobic metabolism becomes limiting for ATP production as occurs during strenuous physical activity. Anaerobic metabolism is considerably less efficient than aerobic metabolism, in terms of energy produced. Anaerobic glycolysis is typically needed to produce energy when the oxygen supply to muscle is limited, such as during short duration high-intensity activity (Casey A, Greenhaff PL. Does dietary creatine supplementation play a role in skeletal muscle metabolism and performance? Am J Clin Nutr. 2000 Aug;72(2 Suppl):607S-17S). Phosphoscreatine is the phosphagen utilized by humans to store energy in a form that can quickly be used to regenerate ATP.
- the enzyme creatine kinase catalyzes a reversible reaction in which phosphocreatine is used as a source of phosphate to regenerate ATP from ADP (adenosine phosphate).
- Phosphocreatine provides a rapid source of ATP but is very limited, only supplying enough energy for a few seconds of high-intensity activity.
- Lactate in turn, is used to regenerate nicotinamide adenine dinucleotide (NAD+), an important cofactor needed for glycolysis (Robergs RA, Ghiasvand F, Parker D. Biochemistry of exercise-induced metabolic acidosis. Am J Physiol Regul Integr Comp Physiol. 2004 Sep;287(3):R502-16).
- NAD+ nicotinamide adenine dinucleotide
- Lactic acid has been thought to be a toxic waste product responsible for muscle fatigue, reduced performance and muscle pain following intense exercise. This has largely been due to the coincidental lowered pH associated with intense exercise and increased muscle lactate. As such, this has been termed “lactic acidosis” and has been theorized to be caused by the production of lactic acid, which acidifies or lowers the pH by losing a proton (H + ) in bodily tissues and fluids.
- lactate due to recent evidence is being viewed as an essential component of intermediary metabolism and no longer a metabolic waster product (Brooks G. The Lactate Shuttle. International Society of Sports Nutrition Conference Proceedings. Journal of the International Society of Sports Nutrition. 2006. 3(l)S30-S43). Therefore, in fact, the cellular presence and production of lactate, or lactic acid, has been suggested to be beneficial for prolonging exercise (Messonnier L, Denis C, Feasson L, Lacour JR.
- lactate An elevated sarcolemmal lactate (and proton) transport capacity is an advantage during muscle activity in healthy humans. J Appl Physiol. 2006 JuI 27; [Epub ahead of print]). It should be noted that "lactic acid” does not exist as an acid under normal physiological conditions but rather as a lactate anion. Additionally, not only does the production of lactate assist in the regeneration of NAD+ but it also consumes a proton which buffers against metabolic acidosis, As such, lactate likely does not cause or contribute to metabolic acidosis. Furthermore, lactate has been shown to be a key fuel source and the concept of the "lactate shuttle" has been largely supported by experimental evidence (Brooks GA. Lactate shuttles in nature. Biochem Soc Trans.
- lactate shuttle refers to the transport or "shuttling" of lactate, both intracellular Iy and intercellularly.
- MCTs membrane-bound monocarboxylate transporters
- lactate metabolism a new paradigm for the third millennium. J Physiol. 2004 JuI l;558(Pt l):5-30). Muscles at rest produce and release low levels of lactate with little uptake. During periods of short duration but high-intensity muscle activity, muscles produce and release higher levels of lactate into the blood.
- lactate produced from glycolysis is transported from the cytosol into the mitochondria where it is subsequently converted to pyruvate. As pyruvate, it can be utilized in the citric acid cycle.
- the intracellular lactate shuttle may be utilized to supply the cell with increased energy.
- the cell-to-cell lactate shuttle may be utilized to supply additional, distal cells with increased energy. It would therefore be advantageous to improve the energy supply to muscle and other bodily systems, organs, tissues or cells through enhancing the production and utilization of endogenous fuel sources i.e. lactate, in a mammal.
- the present invention comprises methods and compositions for improving the energy status of a mammal, by enhancing the usage of lactate in said mammal wherein the usage of lactate is enhanced via the administration of an adrenergic receptor agonist and by an insulinotropic agent. Furthermore, usage of lactate is enhanced by the administration lactate, lactate analogues, or precursors of lactate.
- the term "nutritional composition” includes dietary supplements, diet supplements, nutritional supplements, supplemental compositions and supplemental dietary compositions or those similarly envisioned and termed compositions not belonging to the conventional definition of pharmaceutical interventions as is known in the art.
- "nutritional compositions” as disclosed herein belong to the category of compositions having at least one physiological function when administered to a mammal by conventional routes of administration.
- the dosage form of the nutritional composition may be provided in accordance with customary processing techniques for herbal and nutritional compositions in any of the forms mentioned above.
- the nutritional composition set forth in the example embodiment herein disclosed may contain any appropriate number and type of excipients, as is well known in the art.
- lactate usage or “usage of lactate” refers to the involvement of lactate as an energy source. It is understood that the usage of lactate may be enhanced or improved by a number of non-mutually exclusive mechanisms including, but not limited to; increased availability of lactate or lactate precursors, increased production or synthesis of lactate or lactate precursors, increased secretion of lactate or lactate precursors from cells, increased transport of lactate or lactate precursors within or between cells and enhanced uptake of lactate or lactate precursors by cells. Other mechanisms of improving lactate usage will be apparent to one of skill in the art.
- derivatives of refers to any compound resulting from modification to the referred parent compound.
- modifications for producing derivatives are numerous and include but are not limited to; esterification, acetylation, silylatiion and alkylation.
- Those of skill in the art will readily recognize additional reactions suitable for producing derivatives. Such reactions are known to improve parameters such as stability or absorption.
- derivatives of also refers to compounds commonly referred to as pro-drugs, which are inactive precursors of active compounds that become active within the body after reaction with endogenous metabolic processes.
- derivatives of also refers to precursors of parent compounds that will be reacted within the body by endogenous metabolic processes to form the parent compound.
- insulinotropic refers to any process, activity or effect resulting in an increase in the activity of insulin. This is usually through increasing the production and secretion of insulin but as used herein, the term “insulinotropic” also includes other mechanisms of increasing the activity of insulin which may include but are not limited to: increasing the binding of insulin, increasing the stability of insulin and increasing the plasma half- life of insulin.
- the present invention provides a method for improving the energy status of a mammal, by increasing the usage of a natural endogenous fuel source in said mammal.
- the present invention provides a mechanism of improving the energy status of a mammal, by increasing the usage of lactate in said mammal.
- lactate By way of enhancing the use of lactate there will result an overall improvement in the energy status of said mammal, both at times of rest and during physical activity, particularly during strenuous physical activity.
- the improved energy status will be of benefit to both cells directly involved in said physical activity e.g.
- skeletal muscle cells and cardiac muscle cells and cells which may not be directly involved in physical activity such as, for example, liver cells, unrecruited skeletal muscle cells including, but not limited to myocytes and satellite cells, and brain cells including, but not limited to neurons, glial derived cells such as microglia and astroglia, and oligodendrial cells, via transmission of lactate through the circulatory system.
- Lactic acid (CAS 50-21-5) is a constant and normal product of metabolism and exercise.
- lactate lactate " anion)
- protons H +
- lactate-precursors can be employed as a method to elevate bodily lactate levels. It is understood by the inventors that increasing the bioavailability of endogenous precursors of lactate will increase the conversion of lactate precursors to lactate, thereby increasing the net bioavailable levels of lactate.
- Certain embodiments of the present invention comprise pyruvate or derivatives of pyruvate as a precursor of lactate. Pyruvate and lactate are capable of interconversion (Philp A, Macdonald
- the amount of pyruvate or derivatives of pyruvate in a serving of the composition of the present invention is from about 1 mg to 1000 mg.
- kits for treating neurological disorders comprise glutamine, which can be metabolized to increase lactate, or derivatives of glutamine.
- the amount of glutamine or derivatives of glutamine in a serving of the present invention are from about 0.05 g to about 5.00 g. It is understood that those of skill in the art will recognize additional suitable lactate precursors that are included within the scope of the present invention.
- Adrenergic Receptors are included within the scope of the present invention.
- Adrenergic receptors are a class of receptors which respond to catecholamines.
- Catecholamines are a class of chemical compounds derived from the amino acid tyrosine. Furthermore, the most abundant catecholamines are the neurotransmitters epinephrine, norepinephrine and dopamine.
- Epinephrine also known as adrenaline, is both a hormone and neurotransmitter.
- the principle role of epinephrine lies within the realm of stress responses. Epinephrine binds to and stimulates alpha-adrenergic receptors in liver cells and beta-adrenergic receptors in liver and muscle cells.
- Propanolol, a pharmacological agent is a beta-adrenergic receptor blocker commonly used to counter the effects of epinephrine and to treat hypertension.
- beta-andrenergic receptors in humans results in a combination of decreased lactate production and decreased lactate uptake after intense exercise (Kaiser P, Tesch PA. Effects of acute beta-adrenergic blockade on blood and muscle lactate concentration during submaximal exercise. Int J Sports Med. 1983 Nov;4(4):275-7).
- Beta-adrenergic receptor agonists also show potential use at promoting increases in muscle growth or hypertrophy, particularly for the treatment of muscle-wasting disorders, sacropenia, or muscle injury (Beitzel F, Gregorevic P, Ryall JG, Plant DR, Sillence MN, Lynch GS. Beta2- adrenoceptor agonist fenoterol enhances functional repair of regenerating rat skeletal muscle after injury. J Appl Physiol. 2004 Apr;96(4): 1385-92). Stimulation of beta-adrenergic receptors causes increases in intracellular levels of the messenger molecule cyclic adenosine monophosphate (cAMP), important for intracellular signal transduction.
- cAMP messenger molecule cyclic adenosine monophosphate
- beta-adrenergic receptors inhibits the uptake of lactate by cells and possibly its production
- stimulation of said receptors would stimulate lactate uptake. Therefore, agents which stimulate alpha- and beta-adrenergic receptors or beta-adrenergic receptors alone i.e. adrenergic agonists, may stimulate the production, release and uptake of lactate by cells where the lactate could be used for immediate energy or converted to glycogen for storage. Therefore, it would be advantageous to use agents which increase the activity of adrenergic receptors to enhance the usage of lactate as a fuel source.
- Caffeine has been found to increase the production of lactate in healthy humans (Astrup A, Toubro S, Cannon S, Hein P, Breum L, Madsen J. Caffeine: a double-blind, placebo-controlled study of its thermogenic, metabolic, and cardiovascular effects in healthy volunteers. Am J Clin Nutr. 1990 May;51(5):759-67) Therefore, caffeine, via increasing epinephrine, an alpha- and beta- adrenergic agonist, can increase the production and release of lactate.
- increasing adrenergic receptor activity via adrenergic receptor agonists may be accomplished through a number of non-mutually exclusive mechanisms including but not limited to; increasing the levels of adrenergic receptor protein-coding mRNA, increasing the levels of adrenergic receptors via the increased expression of new receptor proteins, increasing the functional biological activity of pre-existing receptor proteins, and increasing the availability or activity of adrenergic receptor substrate.
- Other mechanisms of increasing the activity of adrenergic receptors will be apparent to those of skill in the art.
- Various embodiments of the present invention comprise caffeine or derivatives of caffeine as an agent with adrenergic agonist activity.
- a serving of the present invention comprises from about 5 mg to about 500 mg of caffeine or derivatives of caffeine.
- inventions of the present invention comprise epinephrine or derivatives of epinephrine as an agent with adrenergic agonist activity.
- a serving of the present invention comprises from about 0.01 mg to about 1 mg of epinephrine or derivatives of epinephrine.
- Other embodiments of the present invention comprise norepinephrine or derivatives of norepinephrine as an agent with adrenergic agonist activity.
- a serving of the present invention comprises from about 0.01 mg to about 1 mg of norepinephrine or derivatives of norepinephrine.
- inventions of the present invention comprise dopamine or derivatives of dopamine as an agent with adrenergic agonist activity.
- a serving of the present invention comprises from about 0.01 mg to about 2 mg of dopamine or derivatives of dopamine.
- alpha- and beta-adrenergic agonists either alone or in combination will enhance the usage of lactate as an energy source. It is further understood that the specific adrenergic agonists herein described represent examples and are in no way construed to be in any way limiting. Other suitable adrenergic agonists will be known to those of skill in the art and are within the scope of the present invention. Insulin and Insulinotropic Activity
- Insulin is a hormone secreted by the pancreas in humans in response to glucose in the plasma and is involved in glucose uptake, thereby lowering blood glucose levels. Postprandial blood glucose levels rise and stimulate the secretion of insulin. It has been shown that high levels of insulin induce increased lactate production in cultured human cells (Lockette W, Kirkland K, Farrow S. Alpha 2-adrenergic agonists increase cellular lactate efflux. Hypertension. 1996 May;27(5):l 104-7). In healthy humans, increases in insulin levels have been shown to stimulate the release of lactate from skeletal muscle, which is further enhanced in endurance-trained individuals (Juel C, Holten MK, DeIa F.
- a number of dietary constituents other than glucose are known to stimulate insulin secretion.
- Certain amino acids, such as arginine, or amino acid combinations, such as leucine and glutamine, have also been shown to increase the secretion of insulin from cultured normal human pancreatic cells (Henquin JC, Dufrane D, Nenquin M. Nutrient control of insulin secretion in isolated normal human islets. Diabetes. 2006 Dec;55(12):3470-7).
- Leucine by itself is known to be the most insulinotropic agent, with the exception of glucose (MacDonald MJ, McKenzie DI, Kaysen JH, Walker TM, Moran SM, Fahien LA, Towle HC.
- pyruvate methyl pyruvate
- Zawalich WS Zawalich KC. Influence of pyruvic acid methyl ester on rat pancreatic islets. Effects on insulin secretion, phosphoinositide hydrolysis, and sensitization of the beta cell. J Biol Chem. 1997 Feb 7;272(6):3527-31).
- Embodiments of the present invention comprise compounds possessing insulinotropic effects.
- insulinotropic agents A number of specific examples of insulinotropic agents have been discussed and it is herein understood that other suitable insulinotropic agents also within the scope of the present invention will be apparent to those of skill in the art.
- the insulinotropic agents are present in amounts sufficient to cause an effective increase in blood insulin levels.
- lactate salts or lactate-precursors in combination with agents that increase adrenergic receptor activity or agents with insulinotropic activity that will act to enhance the usage of lactate.
- the nutritional composition may be consumed in any form.
- the dosage form of the nutritional composition may be provided as, e.g. a powder beverage mix, a liquid beverage, a ready-to-eat bar or drink product, a capsule, a liquid capsule, a tablet, a caplet, or as a dietary gel.
- the preferred dosage forms of the present invention are provided as a capsule or as a liquid capsule.
- the nutritional supplement may be administered in a dosage form with controlled release characteristics i.e. time-release.
- the controlled release may be in the form of either delayed release of active constituents or gradual, prolonged release i.e. sustained-release.
- the goal of such strategies is to extend the period of bioavailability or to meet a specific window for optimal bioavailability.
- the nutritional supplement may be administered in the form of a multicompartment capsule which combines both immediate release and time-release characteristics. Differential release characteristics may be achieved through modifications to the active constituents, through specific properties of the compartments, the use of specific excipients with desired properties, or a combination of these.
- the compartments of such a multi-compartment capsule may be defined by physical divisions within the capsule or smaller spatial units within the capsule or compartments of the capsule such as beads or beadlets.
- Individual components of the nutritional supplement may be contained in differential compartments of such a capsule such that specific components are released rapidly while others are time-released.
- a uniform mix of the various components of the present invention may be divided into both immediate release and time-release compartments to provide a multi-phasic release profile.
- FIG. 11/709,526 entitled “Method For Increasing The Rate And Consistency Of Bioavailability Of Supplemental Dietary Ingredients” filed February 21, 2007, which is herein fully incorporated by reference discloses the use of particle-milling for the purposes of increasing the rate of bioavailability following oral administration of components comprising supplemental dietary compositions.
- the increased bioavailability of a compound or ingredients is achieved via a reduction in particle size using a "fine-milling" technique.
- micronization milling, particle-milling, and fine-milling are used interchangeably, wherein they refer to a technology, process and end-products involved in or leading to a narrowing of particle size range and a concomitant reduction in the average particle size.
- acceptable milled-particle sizes are in the range of from about 1 nanometer to about 500 microns.
- solubility resulting from fine-milling will lead to improvements in characteristics in which solubility and reduced particle size likely play a role.
- the components of the present invention may be fine- milled in order to quicken the rate of dissolution.
- solubility due to the relationship between solubility and dissolution, the amount of a substance in solution at any given time is dependent upon both dissolution and solubility. Furthermore, it is understood by way of extension that increasing the rate of dissolution . of a given substance acts to reduce the time to dissolution of a given solute or substance in a given solvent. However, the absolute solubility of said solute does not increase with infinite time. Thus, increasing the rate of dissolution of a substance will increase the amount of said substance in solution at earlier points in time, thus increasing the rate of bioavailability of said substance at earlier times upon oral administration. The increase in the rate of bioavailability will allow better and quicker compound transfer to the systemic parts of the body.
- Micronization is a technique which has been used as a method of sizing solid compounds to fine powders. Following a micronization process, compounds and more specifically poorly soluble compounds are transformed into fine powders which can then be transformed into suitable, stable and patient-compliant dosage forms. These forms, for the purposes of the present invention are derived for oral administration. Micronization techniques offer an advantage over larger forms of compounds and poorly soluble compounds - following micronization, compounds have higher surface area to volume ratio. This provides for, as compared to physically coarse compounds, an ultrafine micronized powder that has a significantly increased total surface area. Mathematically, cross-sectional surface area increases with the square of the radius, while volume increases with the cube of the radius.
- the volume of the particle decreases at a faster rate than the surface area leading to an increase in the ratio of surface area to volume.
- decreasing the size of a particle can increase its rate of dissolution via increasing the surface area to volume ratio. In the case of solubility, this increase in relative surface area allows for greater interaction with solvent.
- the components of the present invention may be present in portions fine-milled to varying degrees thereby providing a multi-phasic dissolution profile as is disclosed in the preceding application reference.
- a nutritional supplement is provided in the form of a capsule for use by individuals engaged in regular physical activity wishing to improve athletic performance.
- Each serving of the nutritional supplement comprises the following: about 220 mg of anhydrous caffeine and about 100 mg of pyruvate.
- Example 2 A nutritional supplement is provided in the form of a liquid capsule for use by individuals engaged in regular endurance training wishing to increase endurance and exercise duration. Each serving of the nutritional supplement comprises the following: about 100 mg of caffeine, about 1000 mg L-glutamine and about 10 mg of ethyl pyruvate. One serving is taken three to five times daily to enhance the availability of lactate for energy.
- Example 3
- a nutritional supplement is provided in the form of a sustained-release capsule for use by individuals engaged intense endurance training wishing to improve athletic performance.
- Each serving of the nutritional supplement comprises the following: about 250 mg of caffeine, about 5.0 g of L-leucine, about 500 mg L-glutamine, about 10 mg of ethyl pyruvate, about 10 mg of methyl pyruvate and about 10 mg of methyl succinate.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a method of improving the energy status of an individual by enhancing the usage of lactate. Improved lactate usage is accomplished through a composition comprising lactate precursors, adrenergic receptor agonists and insulinotropic agents.
Description
Improving the Energy Status of an Individual by Enhanced Usage of an
Endogenous Fuel Source
Field of the Invention
The present invention relates to methods and compositions for improving the energy status of an individual by enhancing the usage of an endogenously produced energy source.
Background of the Invention
There are three main metabolic pathways utilized by humans to produce energy in the form of adenosine triphosphate (ATP): oxidative respiration, anaerobic glycolysis and the phosphagen system (Lanza IR, Befroy DE, Kent-Braun JA. Age-related changes in ATP-producing pathways in human skeletal muscle in vivo. J Appl Physiol. 2005 Nov;99(5): 1736-44).
Under conditions where oxygen is available, oxidative respiration in the mitochondria generates ATP. Aerobic metabolism involves a complicated series of reactions to produce energy. In terms of efficiency, aerobic metabolism provides more energy than anaerobic metabolism. Aerobic respiration is used to provide energy during endurance-type activities which are typified by low- to moderate-intensity activities maintained for long durations (Korzeniewski B. Regulation of oxidative phosphorylation in different muscles and various experimental conditions. Biochem J. 2003 Nov l;375(Pt 3):799-804).
Anaerobic glycolysis is utilized for energy when aerobic metabolism becomes limiting for ATP production as occurs during strenuous physical activity. Anaerobic metabolism is considerably less efficient than aerobic metabolism, in terms of energy produced. Anaerobic glycolysis is typically needed to produce energy when the oxygen supply to muscle is limited, such as during short duration high-intensity activity (Casey A, Greenhaff PL. Does dietary creatine supplementation play a role in skeletal muscle metabolism and performance? Am J Clin Nutr. 2000 Aug;72(2 Suppl):607S-17S). Phosphoscreatine is the phosphagen utilized by humans to store energy in a form that can quickly be used to regenerate ATP. The enzyme creatine kinase catalyzes a reversible reaction in
which phosphocreatine is used as a source of phosphate to regenerate ATP from ADP (adenosine phosphate). Phosphocreatine provides a rapid source of ATP but is very limited, only supplying enough energy for a few seconds of high-intensity activity.
Both aerobic and anaerobic metabolisms share the initial steps of substrate processing, whereby blood glucose or muscle glycogen is converted to pyruvate. In the presence of adequate oxygen pyruvate is then used in the citric acid cycle, also known as the Krebs cycle. Glycolysis can proceed so quickly that pyruvate accumulates in the muscle. When this accumulation of pyruvate occurs, the enzyme lactate dehydrogenase converts pyruvate to lactate (Gladden LB. Lactic acid: New roles in a new millennium. Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):395-7). Lactate, in turn, is used to regenerate nicotinamide adenine dinucleotide (NAD+), an important cofactor needed for glycolysis (Robergs RA, Ghiasvand F, Parker D. Biochemistry of exercise-induced metabolic acidosis. Am J Physiol Regul Integr Comp Physiol. 2004 Sep;287(3):R502-16).
Traditionally, Lactic acid has been thought to be a toxic waste product responsible for muscle fatigue, reduced performance and muscle pain following intense exercise. This has largely been due to the coincidental lowered pH associated with intense exercise and increased muscle lactate. As such, this has been termed "lactic acidosis" and has been theorized to be caused by the production of lactic acid, which acidifies or lowers the pH by losing a proton (H+) in bodily tissues and fluids.
A more recent re-interpretation of previous findings in light of new data suggests that lactic acid may in fact not be the cause of the aforementioned exercise-induced metabolic acidosis
(Robergs RA, Ghiasvand F, Parker D. Biochemistry of exercise-induced metabolic acidosis. Am J Physiol Regul Integr Comp Physiol. 2004 Sep;287(3):R502-16). The accumulation of inorganic phosphate and protons, mostly from the hydrolysis of ATP at a rate which exceeds that of ATP regeneration, is supported by evidence to be more likely than lactic acid as the cause of exercise- induced metabolic acidosis.
G. Brooks in an abstract from the 2006 Journal of the International Society of Sports Nutrition Conference Proceeding discloses that the shuttling of lactate through the interstitium and vasculature provides a significant carbon source for oxidation and gluconeogenesis during rest and exercise. Furthermore, adding to the original idea that lactate released from fast glycolytic fibers fuels slow-oxidative fibers, it known now that lactate is shuttled between different cells, organs and tissues to provide an energetic function. Lactate, due to recent evidence is being viewed as an essential component of intermediary metabolism and no longer a metabolic waster product (Brooks G. The Lactate Shuttle. International Society of Sports Nutrition Conference Proceedings. Journal of the International Society of Sports Nutrition. 2006. 3(l)S30-S43). Therefore, in fact, the cellular presence and production of lactate, or lactic acid, has been suggested to be beneficial for prolonging exercise (Messonnier L, Denis C, Feasson L, Lacour JR. An elevated sarcolemmal lactate (and proton) transport capacity is an advantage during muscle activity in healthy humans. J Appl Physiol. 2006 JuI 27; [Epub ahead of print]). It should be noted that "lactic acid" does not exist as an acid under normal physiological conditions but rather as a lactate anion. Additionally, not only does the production of lactate assist in the regeneration of NAD+ but it also consumes a proton which buffers against metabolic acidosis, As such, lactate likely does not cause or contribute to metabolic acidosis. Furthermore, lactate has been shown to be a key fuel source and the concept of the "lactate shuttle" has been largely supported by experimental evidence (Brooks GA. Lactate shuttles in nature. Biochem Soc Trans. 2002 Apr;30(2):258-64). The term "lactate shuttle" as used herein refers to the transport or "shuttling" of lactate, both intracellular Iy and intercellularly. One of the main observations has been that endurance/aerobic training reduces blood lactate levels despite the continued production of lactate from muscle cells, thus giving rise to the concept that, against traditional thinking, lactate and the lactate shuttle must contribute as fuel source to working muscles. The lactate shuttle is facilitated by membrane-bound monocarboxylate transporters (MCTs).
In skeletal muscle, two distinct isoforms have been characterized - MCT-I and MCT-4, each with
different properties. Training has been shown to have effects on the expression of MCTs resulting in more efficient use of lactate, particularly with respect to the clearance of lactate from the blood by increasing its uptake within cells (Dubouchaud H, Butterfield GE, Wolfel EE, Bergman BC, Brooks GA. Endurance training, expression, and physiology of LDH, MCTl , and MCT4 in human skeletal muscle. Am J Physiol Endocrinol Metab. 2000 Apr;278(4):E571-9).
Most lactate is removed through oxidation while the remainder is converted to glucose and glycogen. The hypothesis of the lactate shuttle holds that excess lactate transported both intracellularly (via an intracellular lactate shuttle) and intercellularly (via a cell-to-cell lactate shuttle) for use as immediate fuel or for storage (Gladden LB. Lactate metabolism: a new paradigm for the third millennium. J Physiol. 2004 JuI l;558(Pt l):5-30). Muscles at rest produce and release low levels of lactate with little uptake. During periods of short duration but high-intensity muscle activity, muscles produce and release higher levels of lactate into the blood. During recovery, or during low- to moderate-intensity activity, muscles show a net increase in the uptake of lactate from the blood. Within cells lactate produced from glycolysis is transported from the cytosol into the mitochondria where it is subsequently converted to pyruvate. As pyruvate, it can be utilized in the citric acid cycle.
As there is a need, it would therefore be advantageous to increase the availability and usage of lactate, either through endogenous mechanisms, or through exogenous sources. By increasing the production of lactate within a cell, the intracellular lactate shuttle may be utilized to supply the cell with increased energy. Moreover, by concomitantly increasing the production and/or secretion of lactate from a given cell and increasing the uptake of lactate by another cell, the cell-to-cell lactate shuttle may be utilized to supply additional, distal cells with increased energy. It would therefore be advantageous to improve the energy supply to muscle and other bodily systems, organs, tissues or cells through enhancing the production and utilization of endogenous fuel sources i.e. lactate, in a mammal.
Summary of the Invention
The foregoing needs and other needs and objectives that will become apparent for the following description are achieved in the present invention which comprises methods and compositions for improving the energy status of a mammal, by enhancing the usage of lactate in said mammal wherein the usage of lactate is enhanced via the administration of an adrenergic receptor agonist and by an insulinotropic agent. Furthermore, usage of lactate is enhanced by the administration lactate, lactate analogues, or precursors of lactate.
Detailed Description of the Invention
In the following description, for the purposes of explanations, numerous specific details are set forth in order to provide a thorough understanding of the present invention. It will be apparent, however, to one skilled in the art that the present invention may be practiced without these specific details.
As used herein, the term "nutritional composition" includes dietary supplements, diet supplements, nutritional supplements, supplemental compositions and supplemental dietary compositions or those similarly envisioned and termed compositions not belonging to the conventional definition of pharmaceutical interventions as is known in the art. Furthermore, "nutritional compositions" as disclosed herein belong to the category of compositions having at least one physiological function when administered to a mammal by conventional routes of administration. The dosage form of the nutritional composition may be provided in accordance with customary processing techniques for herbal and nutritional compositions in any of the forms mentioned above. Additionally, the nutritional composition set forth in the example embodiment herein disclosed may contain any appropriate number and type of excipients, as is well known in the art.
As it is used herein, the terms "lactate usage" or "usage of lactate" refers to the involvement of lactate as an energy source. It is understood that the usage of lactate may be enhanced or improved by a number of non-mutually exclusive mechanisms including, but not limited to;
increased availability of lactate or lactate precursors, increased production or synthesis of lactate or lactate precursors, increased secretion of lactate or lactate precursors from cells, increased transport of lactate or lactate precursors within or between cells and enhanced uptake of lactate or lactate precursors by cells. Other mechanisms of improving lactate usage will be apparent to one of skill in the art.
As used herein, the term "derivatives of refers to any compound resulting from modification to the referred parent compound. In is herein understood that the modifications for producing derivatives are numerous and include but are not limited to; esterification, acetylation, silylatiion and alkylation. Those of skill in the art will readily recognize additional reactions suitable for producing derivatives. Such reactions are known to improve parameters such as stability or absorption. The term "derivatives of also refers to compounds commonly referred to as pro-drugs, which are inactive precursors of active compounds that become active within the body after reaction with endogenous metabolic processes. Furthermore, the term "derivatives of also refers to precursors of parent compounds that will be reacted within the body by endogenous metabolic processes to form the parent compound.
As used herein, the term "insulinotropic" refers to any process, activity or effect resulting in an increase in the activity of insulin. This is usually through increasing the production and secretion of insulin but as used herein, the term "insulinotropic" also includes other mechanisms of increasing the activity of insulin which may include but are not limited to: increasing the binding of insulin, increasing the stability of insulin and increasing the plasma half- life of insulin.
The present invention provides a method for improving the energy status of a mammal, by increasing the usage of a natural endogenous fuel source in said mammal. Specifically, the present invention provides a mechanism of improving the energy status of a mammal, by increasing the usage of lactate in said mammal. By way of enhancing the use of lactate there will result an overall improvement in the energy status of said mammal, both at times of rest and during physical activity, particularly during strenuous physical activity. The improved energy status will be of
benefit to both cells directly involved in said physical activity e.g. skeletal muscle cells and cardiac muscle cells, and cells which may not be directly involved in physical activity such as, for example, liver cells, unrecruited skeletal muscle cells including, but not limited to myocytes and satellite cells, and brain cells including, but not limited to neurons, glial derived cells such as microglia and astroglia, and oligodendrial cells, via transmission of lactate through the circulatory system. Lactate/Lactic Acid
Lactic acid Lactate anion Proton
Lactic acid (CAS 50-21-5) is a constant and normal product of metabolism and exercise.
Under typical conditions of physiological pH, nearly all lactic acid dissociates into lactate (lactate" anion) and protons (H+).
For the purposes of the present invention, lactate-precursors can be employed as a method to elevate bodily lactate levels. It is understood by the inventors that increasing the bioavailability of endogenous precursors of lactate will increase the conversion of lactate precursors to lactate, thereby increasing the net bioavailable levels of lactate.
Certain embodiments of the present invention comprise pyruvate or derivatives of pyruvate as a precursor of lactate. Pyruvate and lactate are capable of interconversion (Philp A, Macdonald
AL, Watt PW. Lactate— a signal coordinating cell and systemic function. J Exp Biol. 2005 Dec;208(Pt 24):4561-75). The amount of pyruvate or derivatives of pyruvate in a serving of the composition of the present invention is from about 1 mg to 1000 mg.
Other embodiments of the present invention comprise glutamine, which can be metabolized to increase lactate, or derivatives of glutamine. The amount of glutamine or derivatives of glutamine in a serving of the present invention are from about 0.05 g to about 5.00 g.
It is understood that those of skill in the art will recognize additional suitable lactate precursors that are included within the scope of the present invention. Adrenergic Receptors
Adrenergic receptors are a class of receptors which respond to catecholamines. Catecholamines are a class of chemical compounds derived from the amino acid tyrosine. Furthermore, the most abundant catecholamines are the neurotransmitters epinephrine, norepinephrine and dopamine.
Epinephrine, also known as adrenaline, is both a hormone and neurotransmitter. The principle role of epinephrine lies within the realm of stress responses. Epinephrine binds to and stimulates alpha-adrenergic receptors in liver cells and beta-adrenergic receptors in liver and muscle cells. Propanolol, a pharmacological agent is a beta-adrenergic receptor blocker commonly used to counter the effects of epinephrine and to treat hypertension.
Research has demonstrated that epinephrine increases production and release of lactate from human cells (Lockette W, Kirkland K, Farrow S. Alpha 2-adrenergic agonists increase cellular lactate efflux. Hypertension. 1996 May;27(5): 1104-7). Moreover, in trained males undergoing exercise, epinephrine has been shown to increase both muscle and plasma lactate levels which coincided with enhanced glycogen utilization, glycolysis, and carbohydrate oxidation in muscle (Febbraio MA, Lambert DL, Starkie RL, Proietto J, Hargreaves M. Effect of epinephrine on muscle glycogenolysis during exercise in trained men. J Appl Physiol. 1998 Feb;84(2):465-70) indicating a putative role as a muscular fuel source. Interestingly, patients diagnosed with obstructive sleep apnea syndrome display abnormally high levels of epinephrine relative to normal controls. When these patients exercise, lactate production is increased relative to controls, thus providing a further correlation between epinephrine to lactate production (Bonanni E, Pasquali L, Manca ML, Maestri M, Prontera C, Fabbrini M, Berrettini S, Zucchelli G, Siciliano G, Muni L. Lactate production and catecholamine profile during aerobic exercise in normotensive OSAS patients. Sleep Med. 2004 Mar;5(2): 137-45). It is understood that a blockade of beta-andrenergic receptors in humans results
in a combination of decreased lactate production and decreased lactate uptake after intense exercise (Kaiser P, Tesch PA. Effects of acute beta-adrenergic blockade on blood and muscle lactate concentration during submaximal exercise. Int J Sports Med. 1983 Nov;4(4):275-7).
Beta-adrenergic receptor agonists also show potential use at promoting increases in muscle growth or hypertrophy, particularly for the treatment of muscle-wasting disorders, sacropenia, or muscle injury (Beitzel F, Gregorevic P, Ryall JG, Plant DR, Sillence MN, Lynch GS. Beta2- adrenoceptor agonist fenoterol enhances functional repair of regenerating rat skeletal muscle after injury. J Appl Physiol. 2004 Apr;96(4): 1385-92). Stimulation of beta-adrenergic receptors causes increases in intracellular levels of the messenger molecule cyclic adenosine monophosphate (cAMP), important for intracellular signal transduction.
Since antagonism or blockage of beta-adrenergic receptors inhibits the uptake of lactate by cells and possibly its production, it is understood by the inventor that stimulation of said receptors would stimulate lactate uptake. Therefore, agents which stimulate alpha- and beta-adrenergic receptors or beta-adrenergic receptors alone i.e. adrenergic agonists, may stimulate the production, release and uptake of lactate by cells where the lactate could be used for immediate energy or converted to glycogen for storage. Therefore, it would be advantageous to use agents which increase the activity of adrenergic receptors to enhance the usage of lactate as a fuel source.
Caffeine has been found to increase the production of lactate in healthy humans (Astrup A, Toubro S, Cannon S, Hein P, Breum L, Madsen J. Caffeine: a double-blind, placebo-controlled study of its thermogenic, metabolic, and cardiovascular effects in healthy volunteers. Am J Clin Nutr. 1990 May;51(5):759-67) Therefore, caffeine, via increasing epinephrine, an alpha- and beta- adrenergic agonist, can increase the production and release of lactate.
It is herein understood that increasing adrenergic receptor activity via adrenergic receptor agonists may be accomplished through a number of non-mutually exclusive mechanisms including but not limited to; increasing the levels of adrenergic receptor protein-coding mRNA, increasing the levels of adrenergic receptors via the increased expression of new receptor proteins, increasing the
functional biological activity of pre-existing receptor proteins, and increasing the availability or activity of adrenergic receptor substrate. Other mechanisms of increasing the activity of adrenergic receptors will be apparent to those of skill in the art.
Various embodiments of the present invention comprise caffeine or derivatives of caffeine as an agent with adrenergic agonist activity. A serving of the present invention comprises from about 5 mg to about 500 mg of caffeine or derivatives of caffeine.
Other embodiments of the present invention comprise epinephrine or derivatives of epinephrine as an agent with adrenergic agonist activity. A serving of the present invention comprises from about 0.01 mg to about 1 mg of epinephrine or derivatives of epinephrine. Other embodiments of the present invention comprise norepinephrine or derivatives of norepinephrine as an agent with adrenergic agonist activity. A serving of the present invention comprises from about 0.01 mg to about 1 mg of norepinephrine or derivatives of norepinephrine.
Other embodiments of the present invention comprise dopamine or derivatives of dopamine as an agent with adrenergic agonist activity. A serving of the present invention comprises from about 0.01 mg to about 2 mg of dopamine or derivatives of dopamine.
It is herein understood that alpha- and beta-adrenergic agonists, either alone or in combination will enhance the usage of lactate as an energy source. It is further understood that the specific adrenergic agonists herein described represent examples and are in no way construed to be in any way limiting. Other suitable adrenergic agonists will be known to those of skill in the art and are within the scope of the present invention. Insulin and Insulinotropic Activity
Insulin is a hormone secreted by the pancreas in humans in response to glucose in the plasma and is involved in glucose uptake, thereby lowering blood glucose levels. Postprandial blood glucose levels rise and stimulate the secretion of insulin. It has been shown that high levels of insulin induce increased lactate production in cultured human cells (Lockette W, Kirkland K, Farrow S. Alpha 2-adrenergic agonists increase cellular
lactate efflux. Hypertension. 1996 May;27(5):l 104-7). In healthy humans, increases in insulin levels have been shown to stimulate the release of lactate from skeletal muscle, which is further enhanced in endurance-trained individuals (Juel C, Holten MK, DeIa F. Effects of strength training on muscle lactate release and MCTl and MCT4 content in healthy and type 2 diabetic humans. J Physiol. 2004 Apr l;556(Pt l):297-304). This release of lactate is proportional to glucose uptake and, in the case of exercise, involves an increase in the content of MCTs. Furthermore, ingestion of carbohydrate, which is well known to induce insulin secretion, and exercise each separately increase blood lactate levels in humans (Stevenson EJ, Williams C, Mash LE, Phillips B, Nute ML. Influence of high-carbohydrate mixed meals with different glycemic indexes on substrate utilization during subsequent exercise in women. Am J Clin Nutr. 2006 Aug;84(2):354-60).
Therefore, an exercise-induced increase in lactate levels, which will benefit energy status, will be enhanced by agents that increase the activity of insulin.
A number of dietary constituents other than glucose are known to stimulate insulin secretion. Certain amino acids, such as arginine, or amino acid combinations, such as leucine and glutamine, have also been shown to increase the secretion of insulin from cultured normal human pancreatic cells (Henquin JC, Dufrane D, Nenquin M. Nutrient control of insulin secretion in isolated normal human islets. Diabetes. 2006 Dec;55(12):3470-7). Leucine by itself is known to be the most insulinotropic agent, with the exception of glucose (MacDonald MJ, McKenzie DI, Kaysen JH, Walker TM, Moran SM, Fahien LA, Towle HC. Glucose regulates leucine-induced insulin release and the expression of the branched chain ketoacid dehydrogenase El alpha subunit gene in pancreatic islets. J Biol Chem. 1991 Jan 15;266(2):1335-40). Esters of succinic acid, a precursor of glucose and an intermediate of the energy-producing citric acid cycle, have been shown to have strong insulinotropic activity (Zawalich WS, Zawalich KC. Biochemical mechanisms involved in monomethyl succinate-induced insulin secretion. Endocrinology. 1992 Aug;131(2):649-54). Furthermore, a specific derivative of pyruvate, methyl pyruvate, has demonstrated insulinotropic activity isolated rat pancreas cells (Zawalich WS, Zawalich KC.
Influence of pyruvic acid methyl ester on rat pancreatic islets. Effects on insulin secretion, phosphoinositide hydrolysis, and sensitization of the beta cell. J Biol Chem. 1997 Feb 7;272(6):3527-31).
Embodiments of the present invention comprise compounds possessing insulinotropic effects. A number of specific examples of insulinotropic agents have been discussed and it is herein understood that other suitable insulinotropic agents also within the scope of the present invention will be apparent to those of skill in the art. The insulinotropic agents are present in amounts sufficient to cause an effective increase in blood insulin levels.
Therefore, in terms of energy and lactate usage it is advantageous to supply supplemental sources of lactate such as lactate salts or lactate-precursors in combination with agents that increase adrenergic receptor activity or agents with insulinotropic activity that will act to enhance the usage of lactate.
According to various embodiments of the present invention, the nutritional composition may be consumed in any form. For instance, the dosage form of the nutritional composition may be provided as, e.g. a powder beverage mix, a liquid beverage, a ready-to-eat bar or drink product, a capsule, a liquid capsule, a tablet, a caplet, or as a dietary gel. The preferred dosage forms of the present invention are provided as a capsule or as a liquid capsule.
According to various embodiments of the present invention, the nutritional supplement may be administered in a dosage form with controlled release characteristics i.e. time-release. Furthermore, the controlled release may be in the form of either delayed release of active constituents or gradual, prolonged release i.e. sustained-release. The goal of such strategies is to extend the period of bioavailability or to meet a specific window for optimal bioavailability. Advantageously the nutritional supplement may be administered in the form of a multicompartment capsule which combines both immediate release and time-release characteristics. Differential release characteristics may be achieved through modifications to the active constituents, through specific properties of the compartments, the use of specific excipients with
desired properties, or a combination of these. The compartments of such a multi-compartment capsule may be defined by physical divisions within the capsule or smaller spatial units within the capsule or compartments of the capsule such as beads or beadlets. Individual components of the nutritional supplement may be contained in differential compartments of such a capsule such that specific components are released rapidly while others are time-released. Alternatively, a uniform mix of the various components of the present invention may be divided into both immediate release and time-release compartments to provide a multi-phasic release profile.
Further embodiments of the present invention may employ particle-milling technology for enhanced utility and efficacy. U.S. Patent Application No. 11/709,526 entitled "Method For Increasing The Rate And Consistency Of Bioavailability Of Supplemental Dietary Ingredients" filed February 21, 2007, which is herein fully incorporated by reference discloses the use of particle-milling for the purposes of increasing the rate of bioavailability following oral administration of components comprising supplemental dietary compositions. The increased bioavailability of a compound or ingredients is achieved via a reduction in particle size using a "fine-milling" technique. For the purposes of the present invention, the terms micronization, milling, particle-milling, and fine-milling are used interchangeably, wherein they refer to a technology, process and end-products involved in or leading to a narrowing of particle size range and a concomitant reduction in the average particle size. For the purposes of the present invention, acceptable milled-particle sizes are in the range of from about 1 nanometer to about 500 microns. Further to improving bioavailability, it is understood by the inventors that increased solubility resulting from fine-milling will lead to improvements in characteristics in which solubility and reduced particle size likely play a role. The components of the present invention may be fine- milled in order to quicken the rate of dissolution.
Additionally, U.S. Patent Application No. 11/709,525 entitled "Method for a Supplemental Dietary Composition Having a Multi-Phase Dissolution Profile" filed February 21 , 2007, also herein fully incorporated by reference, discloses that components of the present invention may be
used as portions of both non-milled and fine-milled, in order to provide a bi-phasic dissolution profile.
Conventional oral dosage formulations are bound by the rate of dissolution of the unprocessed substance, thereby limiting the rate of bioavailability of the substance upon oral administration. This is particularly problematic for poorly-soluble compounds which have an inherently low rate of dissolution in that they may be excreted prior to first-pass.
It is herein understood that, due to the relationship between solubility and dissolution, the amount of a substance in solution at any given time is dependent upon both dissolution and solubility. Furthermore, it is understood by way of extension that increasing the rate of dissolution . of a given substance acts to reduce the time to dissolution of a given solute or substance in a given solvent. However, the absolute solubility of said solute does not increase with infinite time. Thus, increasing the rate of dissolution of a substance will increase the amount of said substance in solution at earlier points in time, thus increasing the rate of bioavailability of said substance at earlier times upon oral administration. The increase in the rate of bioavailability will allow better and quicker compound transfer to the systemic parts of the body.
Micronization is a technique which has been used as a method of sizing solid compounds to fine powders. Following a micronization process, compounds and more specifically poorly soluble compounds are transformed into fine powders which can then be transformed into suitable, stable and patient-compliant dosage forms. These forms, for the purposes of the present invention are derived for oral administration. Micronization techniques offer an advantage over larger forms of compounds and poorly soluble compounds - following micronization, compounds have higher surface area to volume ratio. This provides for, as compared to physically coarse compounds, an ultrafine micronized powder that has a significantly increased total surface area. Mathematically, cross-sectional surface area increases with the square of the radius, while volume increases with the cube of the radius. Therefore, as a particle becomes smaller, the volume of the particle decreases at a faster rate than the surface area leading to an increase in the ratio of surface area to volume. By
way of theoretical calculations, decreasing the size of a particle can increase its rate of dissolution via increasing the surface area to volume ratio. In the case of solubility, this increase in relative surface area allows for greater interaction with solvent. Further to such additional embodiments, the components of the present invention may be present in portions fine-milled to varying degrees thereby providing a multi-phasic dissolution profile as is disclosed in the preceding application reference.
Although the preceding specification describes how the energy status of a mammal is improved by enhancing the usage of lactate as a fuel source comprising the aforementioned lactate shuttle through increasing adrenergic receptor agonist epinephrine levels via administration of caffeine or similarly acting adrenergic receptor agonist, it should not be construed as the only mechanism by which adrenergic receptor agonists may be modulated to enhance lactate usage. From consideration of the specification, those of skill in the art may determine other methods wherein adrenergic receptor agonists may be employed to enhance lactate usage and the lactate shuttle system. Although the following examples illustrate the practice of the present invention in three of its embodiments, the examples should not be construed as limiting the scope of the invention. Other embodiments will be readily apparent to one of skill in the art from consideration of the specifications and examples.
Examples Example 1
A nutritional supplement is provided in the form of a capsule for use by individuals engaged in regular physical activity wishing to improve athletic performance. Each serving of the nutritional supplement comprises the following: about 220 mg of anhydrous caffeine and about 100 mg of pyruvate.
One serving is taken by the individual about 30 minutes prior to physical activity in order to enhance the usage of lactate for energy during the ensuing period of physical activity. Example 2 A nutritional supplement is provided in the form of a liquid capsule for use by individuals engaged in regular endurance training wishing to increase endurance and exercise duration. Each serving of the nutritional supplement comprises the following: about 100 mg of caffeine, about 1000 mg L-glutamine and about 10 mg of ethyl pyruvate. One serving is taken three to five times daily to enhance the availability of lactate for energy. Example 3
A nutritional supplement is provided in the form of a sustained-release capsule for use by individuals engaged intense endurance training wishing to improve athletic performance. Each serving of the nutritional supplement comprises the following: about 250 mg of caffeine, about 5.0 g of L-leucine, about 500 mg L-glutamine, about 10 mg of ethyl pyruvate, about 10 mg of methyl pyruvate and about 10 mg of methyl succinate.
One serving is taken twice daily, once upon waking and once again midday, to enhance the availability and usage of lactate for energy throughout the day.
Extensions and Alternatives
In the foregoing specification, the invention has been described with specific embodiments thereof; however, it will be evident that various modifications and changes may be made thereto without departing from the broader spirit and scope of the invention.
Claims
1. A composition for improving the usage of lactate for energy in a mammal comprising; one or more adrenergic receptor agonists; one or more lactate precursors or derivatives of lactate precursors; and one or more insulino tropic agents.
2. The composition of claim 1 wherein; the adrenergic receptor agonist is caffeine or a derivative of caffeine in an amount from about 5 mg to about 500 mg.
3. The composition of claim 2 wherein; the lactate precursor is selected from the group consisting of: glutamine or a derivative of glutamine, and pyruvate or a derivative of pyruvate; and wherein the insulinotropic agent is selected from the group consisting of: leucine or a derivative of leucine, arginine or a derivative of arginine, methyl pyruvate, and methyl succinate.
4. The composition of claim 2 wherein; the lactate precursor is glutamine or a derivative of glutamine; and the insulinotropic agent is leucine or a derivative of leucine.
5. The composition of claim 4 wherein; the amount of glutamine or derivative of glutamine is from about 0.05 g to about
5.00 g; and the amount of leucine or derivative of leucine is from about 10 mg to about 7.50 g.
6. The composition of claim 2 wherein;
the lactate precursor is glutamine or a derivative of glutamine; and the insulinotropic agent is arginine or a derivative of arginine.
7. The composition of claim 6 wherein; the amount of glutamine or derivative of glutamine is from about 0.05 g to about
5.00 g; and the amount of arginine or a derivative of arginine is from about 50 mg to about 5.00 g-
8. The composition of claim 2 wherein; the lactate precursor is pyruvate or a derivative of pyruvate; and the insulinotropic agent is leucine or a derivative of leucine.
9. The composition of claim 8 wherein; the amount of pyruvate or a derivative of pyruvate is from about 1 mg to about 1000 mg; and the amount of leucine or a derivative of leucine is from about 10 mg to about 7.50 g.
10. The composition of claim 2 wherein; the lactate precursor is pyruvate or a derivative of pyruvate; and the insulinotropic agent is arginine or a derivative of arginine.
11. The composition of claim 10 wherein; the amount of pyruvate or a derivative of pyruvate is from about 1 mg to about 1000 mg; and the amount of arginine or a derivative of arginine is from about 50 mg to about 5.00 g-
12. A method of improving the usage of lactate for energy in a mammal comprising the step of administering to the mammal a composition comprising; one or more adrenergic receptor agonist; one or more lactate precursors or derivatives of lactate precursors; and
one or more insulino tropic agents.
13. The method of claim 12 wherein; the adrenergic receptor agonist is caffeine or a derivative of caffeine in an amount from about 5 mg to about 500 mg.
14. The method of claim 13 wherein; the lactate precursor is selected from the group consisting of: glutamine or a derivative of glutamine, and pyruvate or a derivative of pyruvate; and the insulinotropic agent is selected from the group consisting of: leucine or a derivative of leucine, arginine or a derivative of arginine, methyl pyruvate, and methyl succinate.
15. The method of claim 12 wherein; the lactate precursor is glutamine or a derivative of glutamine; and the insulinotropic agent is leucine or a derivative of leucine.
16. The method of claim 15 wherein; the amount of glutamine or derivative of glutamine is from about 0.05 g to about
5.00 g; and the amount of leucine or derivative of leucine is from about 10 mg to about 7.50 g.
17. The method of claim 12 wherein; the lactate precursor is glutamine or a derivative of glutamine; and the insulinotropic agent is arginine or a derivative of arginine.
18. The method of claim 17 wherein; the amount of glutamine or derivative of glutamine is from about 0.05 g to about 5.00 g; and
the amount of arginine or a derivative of arginine is from about 50 mg to about 5.00 g-
19. The method of claim 12 wherein; the lactate precursor is pyruvate or a derivative of pyruvate; and the insulinotropic agent is leucine or a derivative of leucine.
20. The method of claim 19 wherein; the amount of pyruvate or a derivative of pyruvate is from about 1 mg to about 1000 mg; and the amount of leucine or a derivative of leucine is from about 10 mg to about 7.50 g.
21. The method of claim 12 wherein; the lactate precursor is pyruvate or a derivative of pyruvate; and the insulinotropic agent is arginine or a derivative of arginine.
22. The method of claim 21 wherein; the amount of pyruvate or a derivative of pyruvate is from about 1 mg to about 1000 mg; and the amount of arginine or a derivative of arginine is from about 50 mg to about 5.00 g-
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CA2007/001782 WO2009043136A1 (en) | 2007-10-04 | 2007-10-04 | Improving the energy status of an individual by enhanced usage of an endogenous fuel source |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CA2007/001782 WO2009043136A1 (en) | 2007-10-04 | 2007-10-04 | Improving the energy status of an individual by enhanced usage of an endogenous fuel source |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009043136A1 true WO2009043136A1 (en) | 2009-04-09 |
Family
ID=40525792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2007/001782 WO2009043136A1 (en) | 2007-10-04 | 2007-10-04 | Improving the energy status of an individual by enhanced usage of an endogenous fuel source |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009043136A1 (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0353065A1 (en) * | 1988-07-29 | 1990-01-31 | University Of Florida | Compositions and methods for achieving improved physiological response to exercise |
US5716926A (en) * | 1996-07-26 | 1998-02-10 | Paxton K. Beale | Composition of pyruvate and protein and method for increasing protein concentration in a mammal |
US6013290A (en) * | 1997-11-17 | 2000-01-11 | Weinstein; Robert E. | Assemblage of nutrient beverages and regimen for enhancing convenience, instruction, and compliance with exercise supplementation |
CA2409807A1 (en) * | 2001-10-26 | 2003-04-26 | William J. Gillota | Recovery drink formula and method |
US20040120983A1 (en) * | 2002-12-23 | 2004-06-24 | Philip Connolly | Nutritional supplement |
US6784209B1 (en) * | 1999-10-18 | 2004-08-31 | Muscletech Research And Development Inc. | Food supplement for increasing lean mass and strength |
US20050032898A1 (en) * | 2003-07-08 | 2005-02-10 | Ajinomoto Co., Inc. | Oral amino acid composition |
EP1629840A1 (en) * | 2003-05-30 | 2006-03-01 | Riken | Amino acid composition and fluid replacement |
US20060198899A1 (en) * | 2005-03-01 | 2006-09-07 | Gardiner Paul T | Supplemental dietary composition for supporting muscle growth, recovery and strength |
-
2007
- 2007-10-04 WO PCT/CA2007/001782 patent/WO2009043136A1/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0353065A1 (en) * | 1988-07-29 | 1990-01-31 | University Of Florida | Compositions and methods for achieving improved physiological response to exercise |
US5716926A (en) * | 1996-07-26 | 1998-02-10 | Paxton K. Beale | Composition of pyruvate and protein and method for increasing protein concentration in a mammal |
US6013290A (en) * | 1997-11-17 | 2000-01-11 | Weinstein; Robert E. | Assemblage of nutrient beverages and regimen for enhancing convenience, instruction, and compliance with exercise supplementation |
US6784209B1 (en) * | 1999-10-18 | 2004-08-31 | Muscletech Research And Development Inc. | Food supplement for increasing lean mass and strength |
CA2409807A1 (en) * | 2001-10-26 | 2003-04-26 | William J. Gillota | Recovery drink formula and method |
US20040120983A1 (en) * | 2002-12-23 | 2004-06-24 | Philip Connolly | Nutritional supplement |
EP1629840A1 (en) * | 2003-05-30 | 2006-03-01 | Riken | Amino acid composition and fluid replacement |
US20050032898A1 (en) * | 2003-07-08 | 2005-02-10 | Ajinomoto Co., Inc. | Oral amino acid composition |
US20060198899A1 (en) * | 2005-03-01 | 2006-09-07 | Gardiner Paul T | Supplemental dietary composition for supporting muscle growth, recovery and strength |
Non-Patent Citations (2)
Title |
---|
OHTANI M. ET AL.: "Amino acid mixture improves training efficiency in athletes", JOURNAL OF NUTRITION, vol. 136, no. 2, 2006, pages 538S - 543S, XP002614998 * |
T. E. GRAHAM: "Caffeine and exercise", SPORTS MED, vol. 31, no. 11, 2001, pages 785 - 807, XP008084424, DOI: doi:10.2165/00007256-200131110-00002 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jentjens et al. | Determinants of post-exercise glycogen synthesis during short-term recovery | |
Layman | Role of leucine in protein metabolism during exercise and recovery | |
US4687782A (en) | Nutritional composition for enhancing skeletal muscle adaptation to exercise training | |
Aoi et al. | Exercise and functional foods | |
EP3658132B1 (en) | Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases | |
US8101569B2 (en) | Energy status of an individual by enhanced production of an endogenous fuel source | |
EP1973426A2 (en) | Compositions for preventing and reducing delayed onset muscle soreness | |
US20100124587A1 (en) | Creatine-containing vitamin and mineral composition | |
Bruce et al. | Glutamine supplementation promotes anaplerosis but not oxidative energy delivery in human skeletal muscle | |
WO2019053580A1 (en) | Energy drink composition | |
Miller et al. | Metabolic response to provision of mixed protein-carbohydrate supplementation during endurance exercise | |
DE10301393A1 (en) | Food supplement for weight loss and muscle development contains lactoprotein or soya protein, omega-3 fatty acids or vegetable oils and amino acids | |
Jitomir et al. | Leucine for retention of lean mass on a hypocaloric diet | |
Obeid et al. | Effect of diet supplementation with glutamine, dihydroxyacetone, and leucine on food intake, weight gain, and postprandial glycogen metabolism of rats | |
WO2009043136A1 (en) | Improving the energy status of an individual by enhanced usage of an endogenous fuel source | |
CA2602460A1 (en) | Improving the energy status of an individual by enhanced usage of an endogenous fuel source | |
AU2007352854A1 (en) | Branched-chain amino acid composition for improving skeletal muscle protein metabolism | |
Devries et al. | Muscle physiology in healthy men and women and those with metabolic myopathies | |
Nicastro et al. | An overview of branched-chain amino acids in exercise and sports nutrition | |
CN105451732A (en) | Lipid metabolism accelerator | |
KR100198159B1 (en) | Composition for diet | |
US7645794B2 (en) | Composition and method for increasing the anabolic state of muscle cells | |
US7993685B2 (en) | Branched-chain amino acid composition for improving skeletal muscle protein metabolism | |
EP2192898A1 (en) | Composition and method for increasing the anabolic state of muscle cells | |
Gleeson | Biochemistry of exercise |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07855409 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07855409 Country of ref document: EP Kind code of ref document: A1 |